Pages
Products
AAV9-CMV-iCre

AAV9-CMV-iCre

Cat.No. :  AAV00269Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00269Z
Description AAV serotype 9 particles contain codon-improved Cre (iCre) under CMV promoter.
Serotype AAV Serotype 9
Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Adeno-associated viruses (AAVs) are non-enveloped, ~25 nm viruses with a 4.7 kb single-stranded DNA (ssDNA) genome enveloped by a small DNA virus, the Parvoviridae family. The wild-type AAV genome encodes four open reading frames, rep, cap, assembly-activating protein (AAP), and the recently discovered membrane-associated accessory protein (MAAP). The AAV cap gene encodes three capsid subunits, VP1-VP3, which assemble into a T = 1 icosahedral capsid in an approximately 1:1:10 ratio. VP1 contains a unique N-terminal domain (VP1u) containing a phospholipase A2 domain that is believed to be responsible for endosomal escape. The VP1u and VP2 domains contain nuclear localization signals that are also required for viral infection. VP3 is the major capsid subunit that establishes tissue tropism through cellular receptor recognition and antigenic responses by the host. The diversity of serotypes is generally defined by amino acid differences within nine variable regions (VR-I to VR-IX) found in VP3. AAV has recently attracted attention as an effective and validated gene therapy vector. Current classes of AAV vectors enable stable, long-term gene expression, have broad tissue tropism, and exhibit relatively low pathogenicity. To date, three serotype capsids (AAV1, AAV2, and AAV9) have received regulatory approval for commercial use in patients.

Neuronal remodeling and myelination are two fundamental processes during neural development. How they influence each other remains largely unknown, although their coordinated execution is critical for circuit function and is often disrupted in neuropsychiatric diseases. By modulating synaptic transmission, cytoskeletal dynamics, and axonal transport in mouse motor axons, researchers show that local axonal remodeling delays the onset of myelination and node formation. In contrast, glial differentiation does not dictate the outcome of axonal remodeling. Delayed myelination is not due to a limited supply of structural components of the axon-glial unit but rather to increased trafficking of signaling factors that initiate myelination, such as neuregulin. Furthermore, the transport of promyelinating signals is regulated by local cytoskeletal maturation associated with activity-dependent competition. These studies reveal an axon branch-specific fine-tuning mechanism that locally coordinates axonal remodeling and myelination.

To manipulate axonal microtubules, researchers genetically deleted the microtubule-severing enzyme spastin (spastin KO) and confirmed delayed axonal branch removal. Indeed, spastin loss led to accelerated node formation in competing axons (din) compared to WT. This represents a cell-autonomous effect in motor neurons, as confirmed by inducing a subset deletion in conditional spastinfl/fl X TdTomato reporter mice using a Cre-encoding adeno-associated virus (AAV9-CMV-iCre; Figure 1). While axonal remodeling was again found to be delayed, node formation on competing branches was now accelerated (Figure 1C), where TdTomato expression indicated spastin loss. Overall, microtubule mass was increased in spastin-deleted terminal axon branches, while axon caliber was unaffected (Figure 1D), in stark contrast to the increased node formation on competing branches. Nrg1 type III is a candidate for a transported early myelinating signal because this signaling factor needs to reach a critical threshold locally to initiate axon-glial differentiation by activating downstream effectors in SCs, such as ERK1/2 and AKT. To investigate the function of Nrg1 type III during axon remodeling, researchers crossed floxed Nrg1 type III with TdTomato reporter mice and injected neonates with AAV9-CMV-iCre (Figure 1E). As expected, myelination was severely impaired in TdTomato-positive branches compared with internal control axons (Figure 1F-H).

AAV9-mediated spastin deletion promotes myelination on competing branches.Figure 1. AAV9-mediated spastin deletion promotes myelination on competing branches. (Wang M, et al., 2021)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Consistent Results

I’ve been using the AAV9-CMV-iCre vectors for a series of in vivo experiments, and the consistency of the results has been remarkable. The product reliability has allowed us to replicate experiments with accuracy, ensuring confidence in our data and findings.

Germany

04/09/2020

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction